[{"Assets_0_Q2_USD":273937000.0,"CommonStockSharesOutstanding_0_Q2_shares":15043591.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":10588000.0,"NetIncomeLoss_1_Q2_USD":2659000.0,"NetIncomeLoss_2_Q2_USD":5275000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":15446827.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":15473727.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":14879040.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":14849449.0,"StockholdersEquity_0_Q2_USD":185731000.0,"EarningsPerShareBasic_1_Q2_USD":0.18,"EarningsPerShareBasic_2_Q2_USD":0.36,"EarningsPerShareDiluted_1_Q2_USD":0.17,"EarningsPerShareDiluted_2_Q2_USD":0.34,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":59296000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":105922000.0,"Ticker":"EGRX","CIK":"827871","name":"EAGLE PHARMACEUTICALS, INC.","OfficialName":"Eagle Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"635235963.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20180807"}]